Sanofi, GlaxoSmithKline Coronavirus Vaccine Appears Effective, Safe

Pharmaceutical giants Sanofi and GlaxoSmithKline announced on Monday that their coronavirus vaccine candidate showed a strong immune response in adults, with no serious safety concerns.

In their phase two trial, the companies enrolled 722 volunteers aged 18 to 95 years old in the United States and Honduras. A press release from the companies states that participants received two injections 21 days apart at three different dose levels.

Interim results showed the vaccine produced a strong antibody response following the second injection across all doses, with “acceptable tolerability and with no safety concerns.”

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post